by Chris Ryan
TORL-1-23, a Claudin-6 (CLDN6)–targeted antibody-drug conjugate (ADC), led to responses in patients with heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer. Additionally, the agent was well tolerated, according to data from the phase 1 TORL-123-001 … Read more
by Rose McNulty
Mirvetuximab soravtansine showed promise for patients with heavily pretreated FRα-positive, platinum-sensitive ovarian cancer—a challenging patient population to treat—in the phase 2 PICCOLO trial. New data from the study presented at the European Society for Medical Oncology (ESMO) … Read more
by Jason M. Broderick
The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 … Read more
At the ESMO Congress 2024 (Barcelona, 13–17 September), final overall survival (OS) data after a median follow-up of approximately 6 years revealed no benefit of niraparib maintenance over placebo for patients newly diagnosed with advanced ovarian cancer at high risk … Read more
By Linda Winkler Garvin
Clearity’s Perspective: Linda Winkler Garvin has a Masters degree in nursing, adult nurse practitioner training, and over 30 years of healthcare experience. Her story is an example of how even those with a medical background may … Read more
By Linda Winkler Garvin
Clearity’s Perspective: Linda Winkler Garvin has a Masters degree in nursing, adult nurse practitioner training, and over 30 years of healthcare experience. Her story is an example of how even those with a medical background may … Read more
by Barbra Williams Cosentino
If your doctor said, “I’m very sorry, but your cancer is terminal,” you’d obviously be devastated. What if she then added, “The prognosis is that you have about six months left, but with treatments we can … Read more
by Kyle Doherty
A research statement was published by the American Society of Clinical Oncology (ASCO) that describes 4 recommendations for decentralization to improve accessibility of cancer clinical trials.1,2
In the statement, the ASCO panel recommended that the FDA … Read more
Denise’s wife of 33 years, Michelle, lived with ovarian cancer for 13 years. She went through six kinds of chemo, two kinds of radiation, and three clinical trials. But her ovarian cancer came back again and again. She died in … Read more
by University of Birmingham
A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more
by Jax DiEugenio
Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more
by IPM staff
A new study from the Mayo Clinic finds that current screening protocols fail to catch a significant number of individuals with genetic mutations linked to hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome, which increase … Read more
Stereotactic ablative radiotherapy led to promising disease control in patients with metastatic gynecologic cancers, research showed.
by Brielle Benyon
Stereotactic ablative radiotherapy (SABR) can be a promising and tolerable way to control gynecologic cancers, according to research published in JAMA Oncology.
SABR is a type of radiation that is highly focused. It provides an intense … Read more
by Huntsman Cancer Institute at the University of Utah
Newswise — A landmark study from researchers at Huntsman Cancer Institute at the University of Utah (the U), the Spencer Fox Eccles School of Medicine at the U, and Boston University … Read more
by Stephen “Fred” Divers, MD, Chief Medical Officer & Julia Frydman, MD, Medical Director for Palliative Care
“I wish we had done this sooner.” This is something that we hear a lot from our patients and their families when they … Read more
Clearity Perspective: When people like Connie share their ovarian cancer experience, it helps others learn about resources and feel less alone. Connie speaks about how she benefitted from Clearity’s Steps Through OC program by receiving personalized Ovarian Cancer Counseling. Clearity … Read more
by Roman Fabbricatore
Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.
Enforcing survivorship standards may help centers provide services to address the needs of cancer survivors, according to … Read more
by Linda Wang
Physical activity can have many benefits for cancer survivors, from improving their quality of life to potentially making it less likely that their disease will come back. Yet studies have shown that many cancer survivors struggle to … Read more
—No difference in adverse events, clinical benefit, OS for patients with or without waivers
by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
